Previous 10 | Next 10 |
Significant survival benefit observed in VITAL study for birtamimab-treated patients with AL amyloidosis at high risk for early mortality (Mayo Stage IV, HR=0.413, p=0.025, over 9 months) SPA agreement with FDA to enable registration of birtamimab at unprecedented p &l...
Prothena (PRTA) reports 9-month results from long-term extension portion of the Phase 1 study evaluating PRX004, an anti-amyloid immunotherapy for ATTR amyloidosis, a rare inherited disorder characterized by the buildup of amyloid protein in tissues and organs.Results included slowing of...
Slowing of neuropathy progression for all 7 evaluable patients , evidenced by a +1.29 point mean change in NIS , was more favorable than expected progression of +9.2 points Improvement in neuropathy for 3 of these 7 evaluab...
The following slide deck was published by Prothena Corporation plc in conjunction with their 2020 Q3 earnings call. For further details see: Prothena Corporation plc 2020 Q3 - Results - Earnings Call Presentation
Prothena (PRTA): Q3 GAAP EPS of -$0.77 misses by $0.12.Revenue of $0.16M (-23.8% Y/Y) misses by $0.03M.Press Release For further details see: Prothena EPS misses by $0.12, misses on revenue
Net cash used in operating and investing activities was $19.5 million in the third quarter and $61.4 million for the first nine months of 2020; quarter-end cash and restricted cash position of $317.2 million provides funding to advance the R&D pipeline Roche presente...
Gainers: Biogen (BIIB) +40%.Cassava Sciences (SAVA) +26%.Athira Pharma (ATHA) +25%.Digirad (DRAD) +22%.Super Micro Computer (SMCI) +21%.Caesarstone (CSTE) +19%.XPeng (XPEV) +19%.Prothena (PRTA) +18%.TravelCenters of America (TA) +18%.Supernus Pharmaceuticals (SUPN) +18%.Losers: Repr...
Next generation anti- Aβ antibod ies being developed for subcutaneous administration to improve access for patient s with Alzheimer’s disease Multi- i mmunogen Aβ- t au va ccine ...
DUBLIN, Ireland, Oct. 28, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a diverse pipeline of investigational therapeutics for neurodegenerative and rare peripheral amyloid diseases, announced today...
Prothena (PRTA) announces that it and licensee Roche (RHHBY) will advance prasinezumab into a Phase 2b study in patients with early Parkinson's disease ((PD)). It will earn a $60M milestone payment when the first participant is dosed.In April, Roche announced that Part 1 of a Phase 2 study, P...
News, Short Squeeze, Breakout and More Instantly...
Prothena Corporation plc Company Name:
PRTA Stock Symbol:
NASDAQ Market:
Prothena Corporation plc Website:
2024-07-03 23:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-02 10:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Prothena to receive $80 million from Bristol Myers Squibb for exclusive global license to PRX019, a potential treatment of neurodegenerative diseases with an undisclosed target Prothena will initiate a Phase 1 clinical trial for PRX019 in 2024 Prothena Corporation plc (NASDAQ:PRTA),...